4//SEC Filing
Alpine ImmunoSciences, L.P. 4
Accession 0001626199-21-000116
CIK 0001626199other
Filed
Sep 20, 8:00 PM ET
Accepted
Sep 21, 5:18 PM ET
Size
7.7 KB
Accession
0001626199-21-000116
Insider Transaction Report
Form 4
Alpine ImmunoSciences, L.P.
10% Owner
Transactions
- Sale
Common Stock
2021-09-17$9.40/sh−400,000$3,760,000→ 2,600,980 total
Alpine Bioventures GP, LLC
10% Owner
Transactions
- Sale
Common Stock
2021-09-17$9.40/sh−400,000$3,760,000→ 2,600,980 total
Footnotes (2)
- [F1]These shares were sold in a private transaction to an investor in the Issuer simultaneously with the closing of the Issuer's private placement on September 17, 2021.
- [F2]Alpine BioVentures GP, LLC ("ABV LLC") is the general partner of the Reporting Person. Dr. Mitchell Gold and Dr. Jay Venkatesan are the Managing Partners of ABV LLC. Dr. Gold and Dr. Venkatesan are also limited partners of the Reporting Person. By virtue of their positions as Managing Partners of ABV LLC, Dr. Gold and Dr. Venkatesan may be deemed to have voting and investment power with respect to the shares held by the Reporting Person and as a result may be deemed to have beneficial ownership of such shares. Each of Dr. Gold and Dr. Venkatesan disclaims beneficial ownership of the shares held by the Reporting Person, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, Dr. Gold or Dr. Venkatesan is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Documents
Issuer
ALPINE IMMUNE SCIENCES, INC.
CIK 0001626199
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001628571
Filing Metadata
- Form type
- 4
- Filed
- Sep 20, 8:00 PM ET
- Accepted
- Sep 21, 5:18 PM ET
- Size
- 7.7 KB